Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Interleukin 17A promotes diabetic kidney injury.

Ma J, Li YJ, Chen X, Kwan T, Chadban SJ, Wu H.

Sci Rep. 2019 Feb 19;9(1):2264. doi: 10.1038/s41598-019-38811-4.

2.

Trends in Incidence of ESKD in People With Type 1 and Type 2 Diabetes in Australia, 2002-2013.

Koye DN, Magliano DJ, Reid CM, Pavkov ME, Chadban SJ, McDonald SP, Polkinghorne KR, White S, Paul C, Shaw JE.

Am J Kidney Dis. 2019 Mar;73(3):300-308. doi: 10.1053/j.ajkd.2018.10.005. Epub 2018 Dec 19.

PMID:
30579709
3.

Associations of Chronic Kidney Disease Markers with Cognitive Function: A 12-Year Follow-Up Study.

Sacre JW, Magliano DJ, Zimmet PZ, Polkinghorne KR, Chadban SJ, Anstey KJ, Shaw JE.

J Alzheimers Dis. 2018 Oct 25. doi: 10.3233/JAD-180498. [Epub ahead of print]

PMID:
30372677
4.

Long-term outcomes of kidney transplant recipients with end-stage kidney disease attributed to presumed/advanced glomerulonephritis or unknown cause.

Lim WH, Wong G, McDonald SP, Chakera A, Luxton G, Isbel NM, Pilmore HL, Barbour T, Hughes P, Chadban SJ.

Sci Rep. 2018 Jun 13;8(1):9021. doi: 10.1038/s41598-018-27151-4.

5.

Identifying Outcomes that Are Important to Living Kidney Donors: A Nominal Group Technique Study.

Hanson CS, Chapman JR, Gill JS, Kanellis J, Wong G, Craig JC, Teixeira-Pinto A, Chadban SJ, Garg AX, Ralph AF, Pinter J, Lewis JR, Tong A.

Clin J Am Soc Nephrol. 2018 Jun 7;13(6):916-926. doi: 10.2215/CJN.13441217. Epub 2018 May 31.

PMID:
29853616
6.

Blockade of HMGB1 Attenuates Diabetic Nephropathy in Mice.

Chen X, Ma J, Kwan T, Stribos EGD, Messchendorp AL, Loh YW, Wang X, Paul M, Cunningham EC, Habib M, Alexander IE, Sharland AF, Chadban SJ, Wu H.

Sci Rep. 2018 May 29;8(1):8319. doi: 10.1038/s41598-018-26637-5.

7.

Preexisting Cancer in Transplant Candidates: Time for a Change in Practice?

Knoll GA, Chadban SJ.

Transplantation. 2018 Jul;102(7):1037-1038. doi: 10.1097/TP.0000000000002177. No abstract available.

PMID:
29557911
8.

Evolution of Glycemic Control and Variability After Kidney Transplant.

Aouad LJ, Clayton P, Wyburn KR, Gracey DM, Chadban SJ.

Transplantation. 2018 Sep;102(9):1563-1568. doi: 10.1097/TP.0000000000002155.

PMID:
29494418
9.

Survival and Quality of Life Impact of a Risk-based Allocation Algorithm for Deceased Donor Kidney Transplantation.

Calisa V, Craig JC, Howard K, Howell M, Alexander S, Chadban SJ, Clayton P, Lim WH, Kanellis J, Wyburn K, Johnson DW, McDonald SP, Opdam H, Chapman JR, Yang J, Wong G.

Transplantation. 2018 Sep;102(9):1530-1537. doi: 10.1097/TP.0000000000002144.

PMID:
29485512
10.

Novel TOF-MS Means of Quantifying ApoAI Amyloid Protein Load After Combined Liver Kidney Transplantation.

Richards KG, Brennan SO, McCaughan GW, Chadban SJ.

Transplantation. 2018 May;102(5):e192-e193. doi: 10.1097/TP.0000000000002116. No abstract available.

PMID:
29377875
11.

The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis.

Wan SS, Ying TD, Wyburn K, Roberts DM, Wyld M, Chadban SJ.

Transplantation. 2018 Apr;102(4):557-568. doi: 10.1097/TP.0000000000002049.

PMID:
29315141
12.

Chronic kidney disease and the global NCDs agenda.

Neuen BL, Chadban SJ, Demaio AR, Johnson DW, Perkovic V.

BMJ Glob Health. 2017 Jul 6;2(2):e000380. doi: 10.1136/bmjgh-2017-000380. eCollection 2017. No abstract available.

13.

The Authors' Reply.

Alexander SI, Clayton PA, Chadban SJ.

Transplantation. 2017 Nov;101(11):e346. doi: 10.1097/TP.0000000000001912. No abstract available.

PMID:
29059130
14.

The Authors Reply.

Allen PJ, Chadban SJ, Craig JC, Lim WH, Allen RDM, Clayton PA, Teixeira-Pinto A, Wong G.

Kidney Int. 2017 Nov;92(5):1291. doi: 10.1016/j.kint.2017.08.020. No abstract available.

PMID:
29055433
15.

Recurrent glomerulonephritis after kidney transplantation: risk factors and allograft outcomes.

Allen PJ, Chadban SJ, Craig JC, Lim WH, Allen RDM, Clayton PA, Teixeira-Pinto A, Wong G.

Kidney Int. 2017 Aug;92(2):461-469. doi: 10.1016/j.kint.2017.03.015.

PMID:
28601198
16.

Expectations and Experiences of Follow-up and Self-Care After Living Kidney Donation: A Focus Group Study.

Manera KE, Hanson CS, Chapman JR, Kanellis J, Gill J, Craig JC, Chadban SJ, Wong G, Ralph AF, Tong A.

Transplantation. 2017 Oct;101(10):2627-2635. doi: 10.1097/TP.0000000000001771.

PMID:
28538499
17.

Organ Transplantation in Australia.

Alexander SI, Clayton PA, Chadban SJ.

Transplantation. 2017 May;101(5):891-892. doi: 10.1097/TP.0000000000001621. No abstract available.

PMID:
28437382
18.

Clinical Trials for Immunosuppression in Transplantation: The Case for Reform and Change in Direction.

OʼConnell PJ, Kuypers DR, Mannon RB, Abecassis M, Chadban SJ, Gill JS, Murphy B, Nickerson PW, Schold JD, Stock PG, Seron D, Alloway RR, Bromberg JS, Budde K, Jordan SC, Legendre C, Lefaucheur C, Sarwall M, Segev DL, Stegall MD, Tullius SG, Wong G, Woodle ES, Ascher N, Morris RE.

Transplantation. 2017 Jul;101(7):1527-1534. doi: 10.1097/TP.0000000000001648.

PMID:
28207630
19.

The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.

Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ.

Kidney Int. 2017 Apr;91(4):954-963. doi: 10.1016/j.kint.2016.11.008. Epub 2017 Jan 18.

PMID:
28109543
20.

Long-term outcomes of kidney transplantation in people with type 2 diabetes: a population cohort study.

Lim WH, Wong G, Pilmore HL, McDonald SP, Chadban SJ.

Lancet Diabetes Endocrinol. 2017 Jan;5(1):26-33. doi: 10.1016/S2213-8587(16)30317-5.

PMID:
28010785
21.

Donor and Recipient Views on Their Relationship in Living Kidney Donation: Thematic Synthesis of Qualitative Studies.

Ralph AF, Butow P, Hanson CS, Chadban SJ, Chapman JR, Craig JC, Kanellis J, Luxton G, Tong A.

Am J Kidney Dis. 2017 May;69(5):602-616. doi: 10.1053/j.ajkd.2016.09.017. Epub 2016 Nov 23. Review.

PMID:
27889296
22.

Relationship between eGFR Decline and Hard Outcomes after Kidney Transplants.

Clayton PA, Lim WH, Wong G, Chadban SJ.

J Am Soc Nephrol. 2016 Nov;27(11):3440-3446. Epub 2016 Apr 8.

23.

Josette Marie Eris April 7, 1959 to April 6, 2016 TTS Councilor and Professor.

Chadban SJ.

Transplantation. 2016 Aug;100(8):1596. doi: 10.1097/TP.0000000000001337. No abstract available.

PMID:
27454917
24.

Patient awareness and beliefs about the risk factors and comorbidities associated with chronic kidney disease : A mixed-methods study.

Lopez-Vargas PA, Tong A, Howell M, Phoon RK, Chadban SJ, Shen Y, Craig JC.

Nephrology (Carlton). 2017 May;22(5):374-381. doi: 10.1111/nep.12829.

PMID:
27248507
25.

Improving Our Understanding of Quality of Life in CKD.

Wyld ML, Chadban SJ, Morton RL.

Am J Kidney Dis. 2016 Jun;67(6):820-1. doi: 10.1053/j.ajkd.2016.03.412. No abstract available.

PMID:
27211365
26.

Risk-Factor Profile of Living Kidney Donors: The Australia and New Zealand Dialysis and Transplant Living Kidney Donor Registry 2004-2012.

Clayton PA, Saunders JR, McDonald SP, Allen RD, Pilmore H, Saunder A, Boudville N, Chadban SJ.

Transplantation. 2016 Jun;100(6):1278-83. doi: 10.1097/TP.0000000000000877.

PMID:
27123877
27.
28.

Recurrent IgA Nephropathy After Kidney Transplantation.

Wyld ML, Chadban SJ.

Transplantation. 2016 Sep;100(9):1827-32. doi: 10.1097/TP.0000000000001093. Review.

PMID:
26895219
29.

Attitudes and beliefs about deceased organ donation in the Arabic-speaking community in Australia: a focus group study.

Ralph AF, Alyami A, Allen RD, Howard K, Craig JC, Chadban SJ, Irving M, Tong A.

BMJ Open. 2016 Jan 19;6(1):e010138. doi: 10.1136/bmjopen-2015-010138.

30.

Cancer in ESRD: Clear on the Epidemiology, Hazy on the Mechanisms.

Lim WH, Chadban SJ.

J Am Soc Nephrol. 2016 May;27(5):1272-5. doi: 10.1681/ASN.2015091021. Epub 2015 Nov 12. No abstract available.

31.

Waiting Time Between Failure of First Graft and Second Kidney Transplant and Graft and Patient Survival.

Wong G, Chua S, Chadban SJ, Clayton P, Pilmore H, Hughes PD, Ferrari P, Lim WH.

Transplantation. 2016 Aug;100(8):1767-75. doi: 10.1097/TP.0000000000000953.

PMID:
26457605
32.

Nephrologists' Perspectives on Recipient Eligibility and Access to Living Kidney Donor Transplantation.

Hanson CS, Chadban SJ, Chapman JR, Craig JC, Wong G, Tong A.

Transplantation. 2016 Apr;100(4):943-53. doi: 10.1097/TP.0000000000000921.

PMID:
26425873
33.

Cross-sectional analysis of nutrition and serum uric acid in two Caucasian cohorts: the AusDiab Study and the Tromsø study.

Zykova SN, Storhaug HM, Toft I, Chadban SJ, Jenssen TG, White SL.

Nutr J. 2015 May 14;14:49. doi: 10.1186/s12937-015-0032-1.

34.

Cost to government and society of chronic kidney disease stage 1-5: a national cohort study.

Wyld ML, Lee CM, Zhuo X, White S, Shaw JE, Morton RL, Colagiuri S, Chadban SJ.

Intern Med J. 2015 Jul;45(7):741-7. doi: 10.1111/imj.12797.

PMID:
25944415
35.

Research Priorities in CKD: Report of a National Workshop Conducted in Australia.

Tong A, Crowe S, Chando S, Cass A, Chadban SJ, Chapman JR, Gallagher M, Hawley CM, Hill S, Howard K, Johnson DW, Kerr PG, McKenzie A, Parker D, Perkovic V, Polkinghorne KR, Pollock C, Strippoli GF, Tugwell P, Walker RG, Webster AC, Wong G, Craig JC.

Am J Kidney Dis. 2015 Aug;66(2):212-22. doi: 10.1053/j.ajkd.2015.02.341. Epub 2015 May 2.

PMID:
25943716
36.

HbA1c Is Insensitive at Month 3 After Kidney Transplantation.

Clayton PA, Aouad L, Wyburn KR, Eris JM, Chadban SJ.

Transplantation. 2015 May;99(5):e37-8. doi: 10.1097/TP.0000000000000683. No abstract available.

PMID:
25943236
37.

IL-17 deficiency attenuates allograft injury and prolongs survival in a murine model of fully MHC-mismatched renal allograft transplantation.

Kwan T, Chadban SJ, Ma J, Bao S, Alexander SI, Wu H.

Am J Transplant. 2015 Jun;15(6):1555-67. doi: 10.1111/ajt.13140. Epub 2015 Mar 30.

38.

Dangers of broth after transplantation.

Aggarwal S, Sukkar L, Wynter L, Richards K, Cheung J, Chadban SJ.

Nephrology (Carlton). 2015 Apr;20(4):297-9. doi: 10.1111/nep.12391.

PMID:
25810227
39.

Graft and patient outcomes of zero-human leucocyte-antigen-mismatched deceased and live donor kidney transplant recipients.

Lim WH, Gray NA, Chadban SJ, Pilmore H, Wong G.

Transpl Int. 2015 May;28(5):610-8. doi: 10.1111/tri.12542. Epub 2015 Mar 3.

40.

Pregnancy outcomes for kidney transplant recipients with transplantation as a child.

Wyld ML, Clayton PA, Kennedy SE, Alexander SI, Chadban SJ.

JAMA Pediatr. 2015 Feb;169(2):e143626. doi: 10.1001/jamapediatrics.2014.3626. Epub 2015 Feb 2.

PMID:
25642905
41.

The expectations and attitudes of patients with chronic kidney disease toward living kidney donor transplantation: a thematic synthesis of qualitative studies.

Hanson CS, Chadban SJ, Chapman JR, Craig JC, Wong G, Ralph AF, Tong A.

Transplantation. 2015 Mar;99(3):540-54. doi: 10.1097/TP.0000000000000433. Review.

PMID:
25463967
42.

Is it time to increase access to transplantation for those with diabetic end-stage kidney disease?

Chadban SJ, Staplin ND.

Kidney Int. 2014 Sep;86(3):464-6. doi: 10.1038/ki.2014.154.

43.

Macrophages in renal transplantation: Roles and therapeutic implications.

Kwan T, Wu H, Chadban SJ.

Cell Immunol. 2014 Sep-Oct;291(1-2):58-64. doi: 10.1016/j.cellimm.2014.05.009. Epub 2014 Jun 14. Review.

PMID:
24973994
44.

External validation of the estimated posttransplant survival score for allocation of deceased donor kidneys in the United States.

Clayton PA, McDonald SP, Snyder JJ, Salkowski N, Chadban SJ.

Am J Transplant. 2014 Aug;14(8):1922-6. doi: 10.1111/ajt.12761. Epub 2014 Jun 5.

45.

Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.

Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inker LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS.

JAMA. 2014 Jun 25;311(24):2518-2531. doi: 10.1001/jama.2014.6634.

46.

TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy.

Ma J, Chadban SJ, Zhao CY, Chen X, Kwan T, Panchapakesan U, Pollock CA, Wu H.

PLoS One. 2014 May 19;9(5):e97985. doi: 10.1371/journal.pone.0097985. eCollection 2014.

47.

Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy.

Ma J, Wu H, Zhao CY, Panchapakesan U, Pollock C, Chadban SJ.

Int J Clin Exp Pathol. 2014 Jan 15;7(2):481-95. eCollection 2014.

48.

Therapeutic inflammatory monocyte modulation using immune-modifying microparticles.

Getts DR, Terry RL, Getts MT, Deffrasnes C, Müller M, van Vreden C, Ashhurst TM, Chami B, McCarthy D, Wu H, Ma J, Martin A, Shae LD, Witting P, Kansas GS, Kühn J, Hafezi W, Campbell IL, Reilly D, Say J, Brown L, White MY, Cordwell SJ, Chadban SJ, Thorp EB, Bao S, Miller SD, King NJ.

Sci Transl Med. 2014 Jan 15;6(219):219ra7. doi: 10.1126/scitranslmed.3007563.

49.

Knowledge deficit of patients with stage 1-4 CKD: a focus group study.

Lopez-Vargas PA, Tong A, Phoon RK, Chadban SJ, Shen Y, Craig JC.

Nephrology (Carlton). 2014 Apr;19(4):234-43. doi: 10.1111/nep.12206.

PMID:
24428274
50.

Preconditioning with recombinant high-mobility group box 1 protein protects the kidney against ischemia-reperfusion injury in mice.

Wu H, Steenstra R, de Boer EC, Zhao CY, Ma J, van der Stelt JM, Chadban SJ.

Kidney Int. 2014 Apr;85(4):824-32. doi: 10.1038/ki.2013.475. Epub 2013 Dec 18.

Supplemental Content

Loading ...
Support Center